vs
Ginkgo Bioworks Holdings, Inc.（DNA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$33.4M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs -23.8%），Ginkgo Bioworks Holdings, Inc.自由现金流更多（$-47.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DNA vs RGNX — 直观对比
营收规模更大
DNA
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出66.8%
-23.8%
自由现金流更多
DNA
多$5.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -23.8% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-1.41 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARGNX
| Q4 25 | $33.4M | $30.3M | ||
| Q3 25 | $38.8M | $29.7M | ||
| Q2 25 | $49.6M | $21.4M | ||
| Q1 25 | $48.3M | $89.0M | ||
| Q4 24 | $43.8M | $21.2M | ||
| Q3 24 | $89.0M | $24.2M | ||
| Q2 24 | $56.2M | $22.3M | ||
| Q1 24 | $37.9M | $15.6M |
净利润DNARGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-80.8M | $-61.9M | ||
| Q2 25 | $-60.3M | $-70.9M | ||
| Q1 25 | $-91.0M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-56.4M | $-59.6M | ||
| Q2 24 | $-217.2M | $-53.0M | ||
| Q1 24 | $-165.9M | $-63.3M |
毛利率DNARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DNARGNX
| Q4 25 | -211.9% | -190.0% | ||
| Q3 25 | -231.8% | -176.3% | ||
| Q2 25 | -132.1% | -296.3% | ||
| Q1 25 | -184.1% | 13.6% | ||
| Q4 24 | -236.3% | -242.1% | ||
| Q3 24 | -62.0% | -256.6% | ||
| Q2 24 | -396.7% | -251.3% | ||
| Q1 24 | -469.1% | -408.8% |
净利率DNARGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -207.9% | -208.3% | ||
| Q2 25 | -121.6% | -331.8% | ||
| Q1 25 | -188.2% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -63.3% | -246.3% | ||
| Q2 24 | -386.4% | -237.7% | ||
| Q1 24 | -437.3% | -405.4% |
每股收益（稀释后）DNARGNX
| Q4 25 | $-1.41 | $-1.30 | ||
| Q3 25 | $-1.45 | $-1.20 | ||
| Q2 25 | $-1.10 | $-1.38 | ||
| Q1 25 | $-1.68 | $0.12 | ||
| Q4 24 | $-1.91 | $-0.99 | ||
| Q3 24 | $-1.08 | $-1.17 | ||
| Q2 24 | $-4.23 | $-1.05 | ||
| Q1 24 | $-3.32 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $102.7M |
| 总资产 | $1.1B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNARGNX
| Q4 25 | $422.6M | $230.1M | ||
| Q3 25 | $495.5M | $274.2M | ||
| Q2 25 | $559.4M | $323.3M | ||
| Q1 25 | $325.3M | $267.9M | ||
| Q4 24 | $561.6M | $234.7M | ||
| Q3 24 | $616.2M | $255.5M | ||
| Q2 24 | $730.4M | $290.4M | ||
| Q1 24 | $840.4M | $338.7M |
股东权益DNARGNX
| Q4 25 | $508.6M | $102.7M | ||
| Q3 25 | $559.8M | $161.5M | ||
| Q2 25 | $613.0M | $213.7M | ||
| Q1 25 | $647.4M | $274.2M | ||
| Q4 24 | $716.1M | $259.7M | ||
| Q3 24 | $797.9M | $301.4M | ||
| Q2 24 | $833.1M | $348.3M | ||
| Q1 24 | $987.3M | $390.7M |
总资产DNARGNX
| Q4 25 | $1.1B | $453.0M | ||
| Q3 25 | $1.2B | $525.2M | ||
| Q2 25 | $1.2B | $581.0M | ||
| Q1 25 | $1.3B | $490.9M | ||
| Q4 24 | $1.4B | $466.0M | ||
| Q3 24 | $1.5B | $519.1M | ||
| Q2 24 | $1.6B | $569.4M | ||
| Q1 24 | $1.6B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | -142.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DNARGNX
| Q4 25 | $-47.7M | $-52.3M | ||
| Q3 25 | $-31.6M | $-56.0M | ||
| Q2 25 | $-40.3M | $-49.3M | ||
| Q1 25 | $-51.5M | $33.6M | ||
| Q4 24 | $-42.4M | $-31.6M | ||
| Q3 24 | $-103.5M | $-40.5M | ||
| Q2 24 | $-84.4M | $-45.5M | ||
| Q1 24 | $-89.3M | $-55.5M |
自由现金流DNARGNX
| Q4 25 | $-47.7M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $-40.3M | $-49.7M | ||
| Q1 25 | $-59.1M | $32.6M | ||
| Q4 24 | $-56.1M | $-32.7M | ||
| Q3 24 | $-118.6M | $-40.9M | ||
| Q2 24 | $-111.4M | $-46.0M | ||
| Q1 24 | $-96.0M | $-56.0M |
自由现金流率DNARGNX
| Q4 25 | -142.8% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | -81.2% | -232.8% | ||
| Q1 25 | -122.4% | 36.6% | ||
| Q4 24 | -128.0% | -154.2% | ||
| Q3 24 | -133.2% | -168.9% | ||
| Q2 24 | -198.2% | -206.2% | ||
| Q1 24 | -252.9% | -358.5% |
资本支出强度DNARGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 15.8% | 1.2% | ||
| Q4 24 | 31.3% | 5.1% | ||
| Q3 24 | 16.9% | 1.3% | ||
| Q2 24 | 48.1% | 2.1% | ||
| Q1 24 | 17.7% | 3.6% |
现金转化率DNARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
